The FDA has approved Pfizer’s #TUKYSA (#tucatinib) + #trastuzumab + #pertuzumab for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
🧪Tucatinib for research use from MedChemExpress: https://www.medchemexpress.com/Irbinitinib.html

#Pfizer has claimed #FDA approval for front-line maintenance use of its oral #HER2inhibitor #Tukysa in #breastcancer, an indication it hopes will unlock the product's growth potential.

pharmaphorum.com/news/pfizers...